Lipoprotein (a) in patients with spontaneous venous thromboembolism

Thrombosis Research

Volumn 120, Issue 1, 2007, Pages 15-20

  Vormittag, Rainer ^a   Vukovich, Thomas ^a   Stain, Milena ^a   Lehr, Stephan ^a   Minar, Erich ^b   Pabinger, Ingrid ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Lipoprotein (a); Pulmonary embolism; Venous thromboembolism; Venous thrombosis

Indexed keywords

LIPOPROTEIN A;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE MARKER; FEMALE; HUMAN; IMMUNOASSAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TURBIDIMETRY; VENOUS THROMBOEMBOLISM;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PREVALENCE; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 34247104650     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.03.002     Document Type: Article

References (41)

1. Danesh J., Collins R., and Peto R. Lipoprotein (a) and coronary heart disease meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
2. Martin S., Pedro-Botet J., Joven J., Simo J.M., Ladona M.G., Pavesi M., et al. Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart disease. J Lab Clin Med 139 3 (2002) 181-187
3. Ridker P.M., Hennekens C.H., and Stampfer M.J. A prospective study of lipoprotein (a) and the risk of myocardial infarction. Jama 270 18 (1993) 2195-2199
4. Ridker P.M., Stampfer M.J., and Hennekens C.H. Plasma concentration of lipoprotein (a) and the risk of future stroke. Jama 273 16 (1995) 1269-1273
5. Marcucci R., Liotta A.A., Cellai A.P., Rogolino A., Gori A.M., Giusti B., et al. Increased plasma levels of lipoprotein (a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 115 8 (2003) 601-605
6. Libourel E.J., Bank I., Meinardi J.R., Balj-Volkers C.P., Koopman K., Van Pampus E.C., et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein (a) to the absolute risk of venous thromboembolism. Haematologica 87 10 (2002) 1068-1073
7. Csaszar A., Karadi I., Juhasz E., and Romics L. High lipoprotein (a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism. Eur J Clin Invest 25 5 (1995) 368-370
8. Ignatescu M., Kostner K., Zorn G., Kneussl M., Maurer G., Lang I.M., et al. Plasma Lp (a) levels are increased in patients with chronic thromboembolic pulmonary hypertension. Thromb Haemost 80 2 (1998) 231-232
9. Lippi G., Bassi A., Brocco G., Manzato F., Marini M., and Guidi G. Lipoprotein (a) concentration is not associated with venous thromboembolism in a case control study. Haematologica 84 8 (1999) 726-729
10. Marz W., Aygoren E., Trommlitz M., Scharrer I., and Gross W. Lipoprotein (a): an indicator of risk in thromboembolic disease?. Klin Wochenschr 68 Suppl 22 (1990) 111-112
11. McColl M.D., Sattar N., Ellison J., Tait R.C., Walker I.D., Packard C.J., et al. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 11 3 (2000) 225-229
12. von Depka M., Nowak-Gottl U., Eisert R., Dieterich C., Barthels M., Scharrer I., et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96 10 (2000) 3364-3368
13. Pabinger I., Grafenhofer H., Kaider A., Ilic A., Eichinger S., Quehenberger P., et al. Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol 21 5 (2001) 874-879
14. Chapman M.J., Huby T., Nigon F., and Thillet J. Lipoprotein (a): implication in atherothrombosis. Atherosclerosis 110 (1994) S69-S75 [Suppl]
15. Biemond B.J., Friedrich W., Koschinsky M.L., Levi M., Sangrar W., Xia J., et al. Apolipoprotein (a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 96 5 (1997) 1612-1615
16. Loscalzo J., Weinfeld M., Fless G.M., and Scanu A.M. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis 10 2 (1990) 240-245
17. Romics L., Karadi I., Csaszar A., and Kostner G.M. Physiological and clinical importance of lipoprotein (a). Tokai J Exp Clin Med 15 2-3 (1990) 149-154
18. Edelberg J.M., and Pizzo S.V. Lipoprotein (a) inhibits plasminogen activation in a template-dependent manner. Blood Coagul Fibrinolysis 2 6 (1991) 759-764
19. Angles-Cano E., and Rojas G. Apolipoprotein (a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site. Biol Chem 383 1 (2002) 93-99
20. Caplice N.M., Panetta C., Peterson T.E., Kleppe L.S., Mueske C.S., Kostner G.M., et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 98 10 (2001) 2980-2987
21. Xiong X., Zhao S., Wang Z., Lo L., and Huang Q. Relationship of lipoprotein (a) to fibrinolytic activities in healthy subjects. Hunan Yi Ke Da Xue Xue Bao 23 6 (1998) 555-557
22. Zhang J., Ren S., and Shen G.X. Glycation amplifies lipoprotein (a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis 150 2 (2000) 299-308
23. Nagy Z., Vastag M., Skopal J., Kolev K., Machovich R., Kramer J., et al. Human brain microvessel endothelial cell culture as a model system to study vascular factors of ischemic brain. Keio J Med 45 3 (1996) 200-206
24. Simon D.I., Fless G.M., Scanu A.M., and Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein (a) and low-density lipoprotein. Biochemistry 30 27 (1991) 6671-6677
25. Kim J., and Hajjar K.A. Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci 7 (2002) d341-d348
26. Gugliucci A., and Ghitescu L. Is diabetic hypercoagulability an acquired annexinopathy? Glycation of annexin II as a putative mechanism for impaired fibrinolysis in diabetic patients. Med Hypotheses 59 3 (2002) 247-251
27. Holmer S.R., Hengstenberg C., Kraft H.G., Mayer B., Poll M., Kurzinger S., et al. Association of polymorphisms of the apolipoprotein (a) gene with lipoprotein (a) levels and myocardial infarction. Circulation 107 5 (2003) 696-701
28. Boomsma D.I., Kaptein A., Kempen H.J., Gevers Leuven J.A., and Princen H.M. Lipoprotein (a): relation to other risk factors and genetic heritability. Results from a Dutch parent-twin study. Atherosclerosis 99 1 (1993) 23-33
29. Boomsma D.I., Knijff P., Kaptein A., Labeur C., Martin N.G., Havekes L.M., et al. The effect of apolipoprotein (a)-, apolipoprotein E-, and apolipoprotein A4-polymorphisms on quantitative lipoprotein (a) concentrations. Twin Res 3 3 (2000) 152-158
30. Noto D., Pace A., Cefalu A.B., Barbagallo C.M., Rizzo M., Marino G., et al. Differential apolipoprotein (a) isoform expression in heterozygosity is an independent contributor to lipoprotein (a) levels variability. Clin Chim Acta 328 1-2 (2003) 91-97
31. Takayama S., Yasumuro Y., Kim J., Ishikawa M., Tsujino D., Matsuo S., et al. An application of apo(a) isoforms for the clinical assessment of Lp (a). J Clin Lab Anal 14 2 (2000) 53-58
32. Sechi L.A., Zingaro L., Catena C., Perin A., De Marchi S., and Bartoli E. Lipoprotein (a) and apolipoprotein (a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int 56 3 (1999) 1049-1057
33. Sari R.A., Polat M.F., Taysi S., Bakan E., and Capoglu I. Serum lipoprotein (a) level and its clinical significance in patients with systemic lupus erythematosus. Clin Rheumatol 21 6 (2002) 520-524
34. Espeland M.A., Marcovina S.M., Miller V., Wood P.D., Wasilauskas C., Sherwin R., et al. Effect of postmenopausal hormone therapy on lipoprotein (a) concentration. PEPI Investigators. Postmenopausal estrogen/progestin interventions. Circulation 97 10 (1998) 979-986
35. Ramharack R., Barkalow D., and Spahr M.A. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein (a) and apolipoprotein (a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol 18 6 (1998) 984-990
36. Maca T.H., Ahmadi R., Derfler K., Ehringer H., Gschwandtner M.E., Horl W., et al. Influence of lipoprotein (a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in Type 2 diabetic patients. Diabet Med 19 4 (2002) 300-306
37. Garnotel R., Monier F., Lefevre F., and Gillery P. Long-term variability of serum lipoprotein (a) concentrations in healthy fertile women. Clin Chem Lab Med 36 5 (1998) 317-321
38. Habib S.S., Aslam M., Naveed A.K., and Sattar A. Lipoprotein (a) and glycaemic control in Pakistani subjects with diabetes mellitus. J Pak Med Assoc 53 2 (2003) 54-59
39. Parsons D.S., Reaveley D.A., Pavitt D.V., and Brown E.A. Relationship of renal function to homocysteine and lipoprotein (a) levels: the frequency of the combination of both risk factors in chronic renal impairment. Am J Kidney Dis 40 5 (2002) 916-923
40. Klausen I.C., Beisiegel U., Menzel H.J., Rosseneu M., Nicaud V., Faergeman O., and The EARS Study and European Atherosclerosis Research Study. Apo(a) phenotypes and Lp (a) concentrations in offspring of men with and without myocardial infarction. Arterioscler Thromb Vasc Biol 15 8 (1995) 1001-1008
41. Xiong Z.W., Wahlqvist M.L., Wattanapenpaiboon N.T., Biegler B.M., Balazs N.D., Xiong D.W., et al. Factors contributing to variation in lipoprotein (a) in Melbourne Anglo-Celtic population. Eur J Clin Nutr 57 3 (2003) 447-454